Belite Bio, Inc. BLTE 深 滬
等待開盤 11-26 09:30:00 美东时间
127.80
-8.200
-6.03%
華盛通- 最 高141.00
- 今 開140.75
- 成交量 53.79万股
- 最 低 115.41
- 昨 收 136.00
- 總市值 44.59亿
- 52周最高 144.99
- 市盈率 靜 --
- 換手率 1.54%
- 52周最低 49.00
- 委 比 56.25%
- 總股本 3489.10万
- 歷史最高 144.99
- 量 比 2.71
- 振 幅 18.82%
- 歷史最低 8.80
- 每 手 1
- 風險率 15.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones gaining around 250 points on Monday...
11-25 00:06
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Mizuho Initiates Coverage On Belite Bio with Neutral Rating, Announces Price Target of $105
Mizuho analyst Graig Suvannavejh initiates coverage on Belite Bio (NASDAQ:BLTE) with a Neutral rating and announces Price Target of $105.
11-21 00:11
Belite Bio Q3 EPS $(0.65) Misses $(0.45) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.45) by 44.44 percent. This is a 132.14 percent decrease over losses of $(0.28) per share from the
11-10 21:03
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
Benchmark Maintains Buy on Belite Bio, Raises Price Target to $132
Benchmark analyst Bruce D. Jackson maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $80 to $132.
10-31 22:08
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Purple Biotech Ltd. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The company has until April 14, 2026, to regain compliance, and if unsuccessful, may have an additional 180 days to meet requirements. The company will monitor its ADS closing bid price and may consider options such as adjusting the ADS-to-ordinary share ratio to address the issue.
10-20 20:00
H.C. Wainwright Remains a Buy on Belite Bio, Inc. ADR (BLTE)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy ratin...
10-16 21:15
